Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 6Metastatic Castration-resistant Prostate Cancer 2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Clear-cell metastatic renal cell carcinoma 1Astrocytoma 1

Interventions

Temozolomide 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiotherapy 4Radiation 3trametinib 2dabrafenib 2Radiotherapy, Intensity-Modulated 2Bevacizumab 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1ribociclib 1Spinal Puncture 1Protons 1Proton Therapy 1Pluvicto 1Nivolumab 1Magnetic Resonance Imaging 1Ipilimumab 1Flucytosine 1Everolimus 1Carboplatin 1CTLA-4 Antigen 1AZD1390 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Pluvicto × 30 days × Clear all
NCT07223034 2026-06-04

A Study of 177Lu-PSMA-617 in People With Gliomas

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
20 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡